Neuroendocrine markers: Role in the development of antidepressants

CNS Drugs

Volumn 10, Issue 2, 1998, Pages 145-157

  Dinan, Timothy G ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ARGIPRESSIN; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; GLUCOCORTICOID RECEPTOR; GROWTH HORMONE; HYDROCORTISONE; PROLACTIN;

DEPRESSION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; PRIORITY JOURNAL; REVIEW;

EID: 0031826861     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199810020-00005     Document Type: Review

References (101)

1. Hayward JN. Functional and morphological aspects of hypothalamic neurones. Physiol Rev 1977; 57: 574-658
2. Everett JW. The mammalian hypothalamo-hypophysial system. In: Jeffcoate SL, Hutchinson JSM, editors. The endocrine hypothalamus. London: Academic Press, 1978: 1-34
3. Givens JR, editor. The hypothalamus. Chicago: Year Book. 1984
4. Flerko B. The hypophysial portal circulation today. Neuroendocrinology 1980; 30: 56-63
5. Asa SL, Kovacs K, Horbath E, et al. Human letal adenohypophysis: electron microscopic and ultrastructural immunocytochemical analysis. Neuroendocrinology 1988; 48: 423-31
6. Doniach I. Histopathology of the pituitary. Clin Endocrinol Metab 1985; 14: 765-89
7. Phifer RF, Midgley AR, Spicer SS. Immunohisiologic and histologic evidence that follicle-stimulating hormone and luteinizing hormone are present in the same cell type of human pars distalis. J Clin Endocrinol 1973; 36: 125-34
8. Checkley SA, Corn TH, Glass IB, et al. The responsiveness of central alpha-2 adrenoceptors in depression. In: Deakin W, editor. The biology of depression. London: Gaskell, 1985: 136-52
9. Dinan TG. Growth hormone as a marker of central neurotransmitters in psychiatric illness. Growth Growth Factors 1992; 7: 163-4
10. O'Keane V, O'Hanlon M, Webb M, et al. D-Fenfluramine/prolactin response throughout the menstrual cycle: evidence for an oestrogen-induced alteration. Clin Endocrinol 1991; 34: 289-92
11. Dinan TG, Barry S, Yatham LN, et al. The reproducibility of the prolactin response to buspirone: relationship to the menstrual cycle. Interclin Psychopharmacol 1990; 5: 143-7
12. Ross RJM, Tsagarkis S, Grossman A, et al. GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: studies with pyridostigmine and GHRH. Clin Endocrinol 1987; 27: 721-33
13. Wass JAH. Growth hormone neuroregulation and the clinical relevance of somatostatin. Clin Endocrinol Metab 1983; 12: 695-724
14. Gomez-Pan A, Rodriguez-Arnao MD. Somatostalin and growth hormone releasing factor: synthesis, location, metabolism and function. Clin Endocrinol Metab 1983; 12: 469-508
15. Bowers CY, Chang J, Momany F, et al. Effects of the enkephalins and enkaphalin analogues on release of pituitary hormones. In: Macintyre I, editor. Molecular endocrinology. Amsterdam: Elsevier. 1977: 287-92
16. Ghigo E, Arvat E, Muccioli G, et al. Growth hormone releasing peptides. Eur J Endocrinol 1997; 136: 445-60
17. Carey DG, Iismaa TP, Ho KY, et al. Potent effects of human galanin in man: growth hormone secretion and vagal blockade. J Clin Endocrinol Metab 1993; 77: 90-3
18. Kask K, Berthold M, Bartsai T. Galanin receptors: involvement in feeding, pain, depression and Alzheimer's disease. Life Sci 1997; 60: 1523-33
19. Cella SG, Picolli GB, Morgese M, et al. Presynaptic alpha-2 adrenergic stimulation leads to growth hormone release in the dog. Life Sci 1984; 34: 447-54
20. Kutukami H, Kato Y, Matsushita N, et al. Effects of neonatal treatment with monosodium glutamate on growth hormone release induced by clonidine and prostaglandin E1 in conscious male rats. Neuroendocrinology 1984; 38: 1-5
21. Casanueva FF, Betti R, Cella SG, et al. Effects of agonists and antagonists of cholinergic neurotransmitters on growth hormone release in the dog. Acta Endocrinol 1983; 103: 15-20
22. Boyd AE, Lebovitz HE, Pfeiffer JB. Stimulation of growth hormone secretion hy I-dopa. N Engl J Med 1970; 283: 1425-9
23. Anderson RA, Mitchell R. Effects of gamma-aminobutyric acid receptor agonists on the secretion of growth hormone, luteinizing hormone, adrenoeorticotrophic hormone and thyroid stimulating hormone from the rat pituitary gland. J Endocrinol 1986; 108: 1-8
24. Girotti G. Effects of a gamma-amino-hydroxybutyric acid derivative, haclofen, on growth hormone and prolactin secretion in man. J Clin Endocrinol Metab 1977; 45: 579-84
25. Ferner N, Johnstone EC, Crow TJ, et al. Anterior pituitary hormone secretion in chronic schizophrenics. Arch Gen Psychiatry 1986; 4: 755-61
26. Lesch KP, Laux G, Pfuller H, et al. Growth hormone response to GH-releasinu hormone in depression. J Clin Endocrinol Metab 1987; 65: 1278-81
27. O'Keane V, Dinan TG. Cholinergic and adrenergic function in depressed and healthy subjects: a neuroendocrine test battery using the growth hormone axis. Hum Psychopharmacol 1994; 9: 171-9
28. Gann H, Riemann D, Stoll S, et al. Growth hormone response to growth hormone releasing hormone and clonidine in depression. Biol Psychiatry 1995; 38: 325-9
29. Eriksson E, Balldin J, Lindstedt G, et al. Growth hormone response to the alpha 2 adrenoceptor agonist, guanfacine, and to the growth hormone releasing hormone in depressed patients and controls. Psychiatry Res 1988; 26: 59-67
30. Krishnan KRR, Manepalli AN, Ritchie CJ, et al. Growth hormone releasing factor stimulation test in depression. Am J Psychiatry 1988; 145: 90-2
31. Thomas R, Beer R, Harris B, et al. GH responses to growth hormone releasing factor in depression. J Affect Disord 1989; 16: 133-7
32. Skare SS, Dysken MW, Billington CJ. A review of GHRH stimulation test in psychiatry. Biol Psychiatry 1994; 36: 249-65
33. Checkley SA, Slade AP, Shur P. Growth hormone and other responses to clonidine in patients with endogenous depression. Br J Psychiatry 1981; 138: 51-5
34. Charney DS, Henninger GR, Sternberg DE. Alpha-2 adrenergic receptor sensitivity and the mechanism of action of anti-depressant therapy. Br J Psychiatry 1983; 142: 265-75
35. Malussek N, Ackenhail M, Hippius H, et al. Effecrs of clonidine on growth hormone released in psychiatric patients and controls. Psychiatry Res 1980; 2: 25-36
36. Katona VL, Healy D, Paykel ES, et al. Growth hormone and physiological responses to clonidine in depression. Psychol Med 1993; 23: 57-63
37. Mitchell PB, Beam JA, Corn TH, et al. Growth hormone response to clonidine after recovery in patients with endogenous depression. Br J Psychiatry 1988; 152: 34-8
38. Dinan TG, Barry S. Responses of growth hormone to desipramine in endogenous and non-endogenous depression. Br J Psychiatry 1990; 156: 680-4
39. Laakmann G, Zygan K, Schoen HW, et al. Effect of receptor Mockers (methysergide, propranolol, phentolamine, yohimbine and prazosin) on desipramine induced pituitary hormone stimulation in humans. I. Growth hormone. Psychoneuroendocrinology 1986; 11: 447-61
40. O'Keane, Dinan TG. Cholinergic and adrenergic function in depressed and healthy subjects: a neuroendocrine test battery using the growth hormone axis. Hum Psychopharmacol 1994; 9: 171-9
41. Janovvsky DF, Davis JM, El-Yousef J, et al. A cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972; 11: 632-5
42. Dilsavei SC. Pathophysiology of cholinoceptor supersensitivity in affective disorders. Biol Psychiatry 1986; 21: 813-29
43. Hobson JA, McCarley RW. Wyzinsky PW. Sleep cycle oscillation: reciprocal discharge by two brainstem neuronal groups. Science 1975; 189: 55-8
44. Sitaram N, Nurenherger JI, Gershon ES, et al. Cholinergic regulation of mood and RRM sleep: potential marker of vulnerability to affective disorder. Am J Psychiatry 1982; 139: 571-76
45. O'Keane V. O'Fynn K, Lucey JV, et al. Pyridostigmine-induced growth hormone responses in healthy and depressed subjects: evidence for cholinergic supersensitivity in depression. Psychol Med 1992; 22: 55-60
46. Reboxetine investigators brochure. Pharmitalia Carlo Erba. CNS Line, 1988 Jul
47. Charney DS, Henninger GR, Reinhard JF, et al. The effect of intravenous L-tryptophan on prolactin, growth hormone and mood in healthy subjects. Psychopharmacology 1982; 77: 217-22
48. Lewis DA, Sherman BM. Serolonergic regulation of prolactin and growth hormone secretion in mall. Acta Endocrinol 1985; 110: 152-7
49. Cowen PJ, Gadhui H, Gosden B, et al. Responses of prolactin and growth hormone to L-tryptophan infusion: effects in normal subjects and schizophrenic patients receiving neuroleptics. Psychopharmacology 1985; 86: 164-9
50. Van Praag HM, Lemus C, Khan R. The pitfalls of serotonin precursors as challengers in hormonal probes of central serotonin activity. Psychopharmacol Bull 1986; 22: 565-70
51. Quattrone A, Schellini G, Direnzo GH, et al. Effect of mid-brain raphe lesion of 5-7-dihydroxytryptamine treatment on the prolactin releasing action of quipazine and d-fenfluramine in rats. Brain Res 1979; 174: 71-9
52. Garattini S, Mennini T, Samanin R. From fenfluramine race-mate to d-fenfluramine: specificity and potency of the effects on the serotonergic system and food intake. Ann N Y Acad Sci 1987; 499: 156-66
53. Goodall EM, Cowen PJ, Franklin M, et al. Ritanserin attenuates anorectic endocrine and thermic responses to d-tenfluramine in healthy volunteers. Psychopharmacology 1993; 112: 461-6
54. O'Keane V, Dinan TG. Prolactin and cortisol responses to d-fenfluramine in major depression: evidence for diminished responsivity of central serolonergic function. Am J Psychiatry 1991; 148: 1009-5
55. American Psychiatry Association. Diagnostic and statistical manual of mental disorders. 3rd ed. rev. Washington. DC: American Psychiatry Association, 1987
56. Coccaro EF, Siever LJ, Klar HM, et al. Serotonergic studies in patients with affective and personality disorders. Arch Gen Psychiatry 1989; 46: 587-99
57. O'Keane V, Moloney E, O'Neill H, et al. Blunted prolactin responses to d-fenfluramine in sociopathy: evidence for subsensitivity of central serotonergic function. Br J Psychiatry 1982; 160: 643-6
58. Koenig JI, Meltzer HY, Gudelsky GA. 5-Hydroxytryptamine IA receptor mediated effects of buspirone, gepirone and ipsapirone. Pharmacol Biochem Behav 1988; 29: 711-5
59. Axelrod J, Reisine TD. Stress hormones: their interaction and regulation. Science 1984; 224: 452-9
60. Dornhorst A, Carlson A, Seif SM. Control of release of adrenocorticotropin and vasopressin by the supraoptic and paraventricular nuclei. Endocrinology 1981; 108: 1420-4
61. Selye H. The stress of life. New York: McGraw-Hill, 1956
62. Cannon WB. The wisdom of the body. New York: Norton. 1932
63. Akana SF, Scribner KA, Bradbury MJ, et al. Feedback sensitivity of the rat hypothalamo-pituitary-adrenal axis and its capacity to adjust to exogenous corticosterone. Endocrinology 1992; 131: 585-93
64. McEwen BS, Davis PG, Parsons B. The brain as a target for steroid hormone action. Annu Rev Neurosci 1979; 2: 65-112
65. Reul JMHM, DeKloet R. Anatomical resolution of two types of corticosterone receptor sites in rat brain with in vitro autoradiography and computerised image analysis. J Steroid Biochem 1986; 24: 269-72
66. Sachar FJ, Hellman L, Fukushima DK, et al. Cortisol production in depressive illness. Arch Gen Psychiatry 1978; 23: 289-98
67. American Psychiatric Association Task Force. The dexamethasone suppression test: an overview of its current status in psychiatry. Am J Psychiatry 1987; 144: 1253-62
68. Carroll BJ. The dexamethasone suppression lest for melancholia. Br J Psychiatry 1982; 140: 292-304
69. Coppen A, Abou-Saleh M, Mill NP, et al. Dexamethasone suppression test in depression and other psychiatric illness. Br J Psychiatry 1983; 142: 498-504
70. Nemeroff CB, Widerlov F, Bissette G, et al. Elevated concentrations of CSF corticotropin-releasing factor, like immunoreactivity in depressed patients. Science 1984; 226: 1342-4
71. Raudsheer FC, Hoogendijk WJG, Stam FC, et al. Increased number of corticotropin-releasing hormone neurones in the hypothalamic paraventricular nuclei of depressed patients. Neuroendocrinology 1994; 60: 436-44
72. Raadsheer FC, Van Heerikhuize JJ, Lucassen PJ, et al. Increased corticotropin-releasing hormone mRNA in paraventricular nucleus of patients with Alzheimer's disease or depression. Am J Psychiatry 1995; 152: 1372-6
73. Holsboer F, Gerken A, Von Bardeleben U, et al. Human corticotrophin-releasing hormone in depression. Biol Psychiatry 1986; 21: 609-11
74. Holshoer F, Spengler D, Heuser I. The role of corticotrophin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia. Prog Brain Res 1992; 93: 385-417
75. Ur E, Dinan TG, O'Keane V, et al. Effect of metyrapone on the pituitary-adrenal axis in depression: relation to dexamethasone suppressor status. Neuroendocrinology 1992; 56: 533-9
76. Modell S, Yassouridis A, Huber J, et al. Corticosteroid receptor function is decreased in depressed patients. Neuroendocrinology 1997; 65: 216-22
77. Holsboer F, Lauer CJ, Schreiher W, et al. Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology 1995; 62: 340-7
78. Amsterdam QAD, Marinelli DL, Arger P, et al. Assessment of adrenal gland volume by computed tomography in depressed patients and healthy volunteers: a pilot study. Psychiatry Res 1987; 21: 189-97
79. Rubin R, Phillips J, Sadow T. Adrenal gland volume in major depression. Arch Gen Psychiatry 1995; 52: 213-8
80. Von Bardeleben U, Holsboer F. Effect of age on the cortisol response to human corticotropin-releasing hormone in depressed patients with dexamethasone. Biol Psychiatry 1991; 29: 1042-50
81. Howl J, Wheatley M. Molecular pharmacology of V 1a vasopressin receptors. Gen Pharmacol 1995; 26: 1143-52
82. Purba JS, Hoogendijk WJG, Hoffman MA, et al. Increased number of vasopressin expressing neurones in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 1996; 53: 137-43
83. Michelson D, Stratakis C, Hill L, et al. Bone mineral density in women with depression. N Eng J Med 1996; 335: 1176-81
84. Thakore JH, Richards PJ, Reznek RH, et al. Increased intraabdominal fat deposition in patients with major depressive illness as measured by computed tomography. Biol Psychiatry 1997; 41: 1140-3
85. Dinan TG. Serotonin and the regulation of hypothalamic-pituitary-adrenal function: a mini-review. Life Sci 1996; 58: 1683-94
86. Lesen KP, Mayer S, Disselkamp-Tietze J, et al. 5-HT-1A receptor responsivity in unipolar depression: evaluation of ipsapirone-induced ACTH and cortisol secretion in patients and controls. Biol Psychiatry 1990; 28: 620-8
87. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122: 509-22
88. Kitayama I, Janson AM, Cintra A, et al. Effects of chronic imipramine treatment on glucocorticoid receptor immunoreactivity in various regions of the brain. J Neural Transm 1988; 73: 191-203
89. Pepin MC, Beaulieu S, Barden N. Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Mol Brain Res 1989; 6: 77-83
90. Barden N, Reul JHM, Holshoer F. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adreno-cortical system? Trends Pharmacol Sci 1995; 18: 6-11
91. Murphy BEP. Treatment of major depression with steroid suppressive drugs. J Steroid Biochem Mol Biol 1991; 39: 239-44
92. Murphy BEP, Dhar V, Ghadirian AM, et al. Response to steroid suppression in major depression resistant to antidepressant therapy. J Clin Psychopharmacol 1991; 11: 121-6
93. Thakore JH, Dinan TG. Cortisol synthesis inhibition: a new treatment strategy for the clinical and endocrine manifestations of depression. Biol Psychiatry 1995; 37: 364-8
94. O'Dwyer AM, Lightman SL, Marks MN, et al. Treatment of major depression with metyrapone and hydrocortisone. J Affect Disord 1995; 33: 123-8
95. Wolkowitz OM, Reus VI, Manfredi F, et al. Ketaconazole administration in hypercortisolemic depression. Am J Psychiatry 1993; 150: 810-2
96. Amsterdam SD, Hornig-Rohan M. Adrenocortical activation and steroid suppression with ketoconazole in refractory depression. Biol Psychiatry 1993; 33: 88A
97. Heinrichs SC, Menzaghi F, Merlo-Pich E, et al. The role of CRF in behavioural aspects of stress. Ann N Y Acad Sci 1995; 771: 92-104
98. Carnazzi E, Aumelas A, Barberis C. A new series of photoactivatable and iodinatable linear vasopressin antagonists. J Med Chem 1994; 37: 1841-9
99. Kumar KB, Karanth KS. Alpha-helical CRF blocks differential influence of corticotropin-releasing factor (CRF) on appetitive and aversive memory retrieval in rats. J Neural Transm 1996; 103: 1117-26
100. Wehster KL, Lewis DB, Torpy DJ, et al. In vivo and in vitro characterisation of antalarmin, a non-peptide corticotropin-releasing hormone (CRH ) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 1996; 137: 5747-50
101. Krishnan KRR, Reed D, Wilson WH, et al. RU486 in depression. Prog Neuropsych Biol Psychiatry 1992; 16: 913-20